News Release

Treatment expectancies and psilocybin vs escitalopram for depression

JAMA Psychiatry

Peer-Reviewed Publication

JAMA Network

About The Study: This randomized controlled trial secondary analysis examines the association between treatment expectancies and the relative efficacy of psilocybin compared with escitalopram for major depressive disorder. 

Corresponding Author: To contact the corresponding author, Ethan Dutcher, MD, PhD, email ethan.dutcher@ucsf.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(10.1001/jamapsychiatry.2024.4387)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being presented at the American College of Neuropsychopharmacology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.4387?guestAccessKey=30ed1c66-ba42-48e8-91ba-d6d50ca38e2b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=120924


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.